News
OGN
13.89
0.00%
0.00
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
NASDAQ · 1d ago
Weekly Report: what happened at OGN last week (1102-1106)?
Weekly Report · 2d ago
Reported Saturday, Organon Presents Real-World Data At ACR Showing 1.3% Switchback Rate After Over 16,000 US Veterans Switched From HUMIRA To HADLIMA
Benzinga · 2d ago
Organon announces poster presentation on Hadlima at ACR Meeting
TipRanks · 3d ago
How Humira Switch Data Will Impact Organon Stock
Simply Wall St · 3d ago
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
Barchart · 4d ago
Can Organon (OGN) Justify Its Valuation Following New VTAMA Phase 3 Data?
Simply Wall St · 4d ago
Organon Updates Pediatric Psoriasis Study as Tapinarof Expansion Nears a Key Milestone
TipRanks · 6d ago
Organon To Present New Analysis Of Phase 3 Data Evaluating VTAMA Cream In Patients With Atopic Dermatitis, At 2026 ACAAI Annual Scientific Meeting
Benzinga · 6d ago
Weekly Report: what happened at OGN last week (1026-1030)?
Weekly Report · 11/02 09:13
Organon (OGN) Stock Shrugs Off Q3 Results As Margin Strain Lingers
Simply Wall St · 11/01 01:26
Organon declares $0.02 dividend
Seeking Alpha · 10/30 12:26
Press Release: Organon Announces Quarterly Dividend
Dow Jones · 10/30 12:25
Organon: Q3 Earnings Snapshot
Barchart · 10/30 07:26
Organon Announces Quarterly Dividend
Barchart · 10/30 07:25
Weekly Report: what happened at OGN last week (1019-1023)?
Weekly Report · 10/26 09:13
Press Release: Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Dow Jones · 10/19 11:32
Weekly Report: what happened at OGN last week (1012-1016)?
Weekly Report · 10/19 09:13
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Barchart · 10/19 06:30
Organon to present interim Phase 3 study results for MIUDELLA
TipRanks · 10/16 11:36
More
Webull provides a variety of real-time OGN stock news. You can receive the latest news about ORGANON & CO through multiple platforms. This information may help you make smarter investment decisions.
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.